Johnson & Johnson's Ethicon closed its acquisition of robotic technologies company Auris Health on April 1.
Ethicon paid $3.4 billion in cash and may pay an additional $2.35 billion if certain milestones are achieved.
The acquisition of Auris Health's robotic technology, which is used in diagnostic and therapeutic lung procedures, fuels Johnson & Johnson's efforts to improve surgical care and lung cancer intervention.
As part of that aim, Johnson & Johnson is developing robotic technologies for general surgery through a collaboration with Verily and expanded its orthopedic portfolio by acquiring Orthotaxy.
More articles on devices:
Washington Orthopaedic Center expanding in new location — 3 insights
Ohio Sports & Spine Institute opens new location — 3 insights
Baptist Health hiring ASC director for Miami Heat development — 3 key insights